Cristi Bundukamara
Psychiatric/Mental Health · Colorado Springs, CONPI 1730312497
Payments from drug & device makers
Across 730 payments — averaging $314.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$86K
- Neurocrine Biosciences, Inc.$47K
- AbbVie$33K
- E.r. Squibb & Sons, L.L.C.$28K
- Axsome Therapeutics, Inc.$15K
- Otsuka America Pharmaceutical, Inc.$15K
- plus $4K from 22 others
What the payments were for
- Consulting fees$42,16518%
- Speaking & faculty fees$148,14664%
- Travel & lodging$25,49311%
- Food & beverage$13,5966%
- Education$3370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 141 | $86,037 |
| Neurocrine Biosciences, Inc. | 123 | $47,203 |
| AbbVie | 119 | $33,378 |
| E.r. Squibb & Sons, L.L.C. | 45 | $28,345 |
| Axsome Therapeutics, Inc. | 27 | $15,477 |
| Otsuka America Pharmaceutical, Inc. | 72 | $15,271 |
| Alkermes, Inc. | 46 | $952 |
| Teva Pharmaceuticals USA, Inc. | 20 | $619 |
| Johnson & Johnson | 23 | $583 |
| Sunovion Pharmaceuticals Inc. | 39 | $349 |
| Lundbeck LLC | 16 | $279 |
| Vanda Pharmaceuticals Inc. | 9 | $239 |
| Almatica Pharma LLC | 5 | $145 |
| Indivior Inc. | 8 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $119 |
| Tris Pharma Inc | 1 | $91 |
| Supernus Pharmaceuticals, Inc. | 6 | $84 |
| Janssen Scientific Affairs, LLC | 2 | $69 |
| Tempus AI, Inc | 3 | $67 |
| Bausch Health US, LLC | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 3 | $50 |
| Eisai Inc. | 4 | $50 |
| USWM, LLC | 2 | $38 |
| Corium, LLC | 2 | $37 |
| Merck | 1 | $22 |
| Livanova USA, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,737 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $101,355 |
| Invega SustennaPaliperidone Palmitate | 15 | $45,110 |
| CaplytaLumateperone Tosylate | 16 | $24,289 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,019 |
| BelsomraSuvorexant | 14 | $6,422 |
| Paliperidone ErPaliperidone | 20 | $5,871 |
| TrintellixVortioxetine Hydrobromide | 12 | $4,824 |
| Quetiapine Fumarate | 73 | $1,431 |
| Buspirone Hcl | 54 | $1,031 |
| Guanfacine Hcl ErGuanfacine Hcl | 28 | $820 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $808 |
| Paroxetine Hcl | 38 | $675 |
| Fluoxetine Hcl | 50 | $642 |
| Oxcarbazepine | 24 | $628 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $47,203 | $101,35513 claims |
| Johnson & JohnsonInvega Sustenna | $583 | $45,11015 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $86,037 | $24,28916 claims |
| Alkermes, Inc.Lybalvi | $952 | $18,01911 claims |
| MerckBelsomra | $22 | $6,42214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $119 | $4,82412 claims |
| Almatica Pharma LLCSertraline Hcl | $145 | $36026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Other psychiatric/mental health in Colorado Springs
- Mark JankelowColorado Springs$287K
- Jennie StormesColorado Springs$12K
- Kimberly SmithColorado Springs$9K
- Lewis SwarthoutColorado Springs$7K
- Ann ChartrandColorado Springs$7K
- Kristin MagnusonColorado Springs$7K
- Shannon GravesColorado Springs$6K
- Alison BakerColorado Springs$6K
- Patricia BursnallColorado Springs$5K
- Kayla PrevidiColorado Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.